These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10076002)

  • 21. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo.
    Taylor NR; Kaplan BE; Swiderski P; Li H; Rossi JJ
    Nucleic Acids Res; 1992 Sep; 20(17):4559-65. PubMed ID: 1408757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel method for selection of tRNA-driven ribozymes with enhanced stability in mammalian cells.
    Sano M; Kuwabara T; Warashina M; Fukamizu A; Taira K
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):341-52. PubMed ID: 12477283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extension of helix II of an HIV-1-directed hammerhead ribozyme with long antisense flanks does not alter kinetic parameters in vitro but causes loss of the inhibitory potential in living cells.
    Homann M; Tabler M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3951-7. PubMed ID: 7524030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1.
    Yu M; Poeschla E; Yamada O; Degrandis P; Leavitt MC; Heusch M; Yees JK; Wong-Staal F; Hampel A
    Virology; 1995 Jan; 206(1):381-6. PubMed ID: 7831794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro selection of a purine nucleotide-specific hammerheadlike ribozyme.
    Vaish NK; Heaton PA; Fedorova O; Eckstein F
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2158-62. PubMed ID: 9482855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cis-cleavage affects hammerhead and hairpin ribozyme steady-state levels differently and has strong impact on trans-targeting efficiency.
    Andäng M; Maijgren-Steffensson C; Hinkula J; Ahrlund-Richter L
    Oligonucleotides; 2004; 14(1):11-21. PubMed ID: 15104892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and characterization of a highly efficient anti-HIV pol hammerhead ribozyme.
    Müller-Kuller T; Capalbo G; Klebba C; Engels JW; Klein SA
    Oligonucleotides; 2009 Sep; 19(3):265-72. PubMed ID: 19732019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A structural analysis of in vitro catalytic activities of hammerhead ribozymes.
    Shao Y; Wu S; Chan CY; Klapper JR; Schneider E; Ding Y
    BMC Bioinformatics; 2007 Nov; 8():469. PubMed ID: 18053134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High cleavage activity and stability of hammerhead ribozymes with a uniform 2'-amino pyrimidine modification.
    Leirdal M; Sioud M
    Biochem Biophys Res Commun; 1998 Sep; 250(1):171-4. PubMed ID: 9735351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of human immunodeficiency virus type 1 reverse transcriptase primer tRNA binding by fluorescence spectroscopy: specificity and comparison to primer/template binding.
    Thrall SH; Reinstein J; Wöhrl BM; Goody RS
    Biochemistry; 1996 Apr; 35(14):4609-18. PubMed ID: 8605212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
    Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
    Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells.
    Kuwabara T; Warashina M; Koseki S; Sano M; Ohkawa J; Nakayama K; Taira K
    Nucleic Acids Res; 2001 Jul; 29(13):2780-8. PubMed ID: 11433023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formation of a catalytically active dimer by tRNA(Val)-driven short ribozymes.
    Kuwabara T; Warashina M; Orita M; Koseki S; Ohkawa J; Taira K
    Nat Biotechnol; 1998 Oct; 16(10):961-5. PubMed ID: 9788354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III.
    Denman RB; Smedman M; Kung L
    Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III.
    Koseki S; Tanabe T; Tani K; Asano S; Shioda T; Nagai Y; Shimada T; Ohkawa J; Taira K
    J Virol; 1999 Mar; 73(3):1868-77. PubMed ID: 9971765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a U16 snoRNA-containing ribozyme library to identify ribozyme targets in HIV-1.
    Unwalla HJ; Li H; Li SY; Abad D; Rossi JJ
    Mol Ther; 2008 Jun; 16(6):1113-9. PubMed ID: 18388915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and anti-HIV-1 activity of ribozymes that cleave HIV-1 LTR.
    Koizumi M; Ozawa Y; Yagi R; Nishigaki T; Kaneko M; Oka S; Kimura S; Iwamoto A; Komatsu Y; Ohtsuka E
    Nucleic Acids Symp Ser; 1995; (34):125-6. PubMed ID: 8841584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity and cleavage site specificity of an anti-HIV-1 hairpin ribozyme in human T cells.
    Yamada O; Kraus G; Leavitt MC; Yu M; Wong-Staal F
    Virology; 1994 Nov; 205(1):121-6. PubMed ID: 7975207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.